Consumer healthcare (CHC) and over-the-counter (OTC) pharmaceutical manufacturers are facing a new challenge in 2026 that has little to do with formulation science or regulatory approvals.
The issue is logistics.
After months of disruption across global shipping networks, freight rates on key pharmaceutical trade lanes have climbed sharply, increasing the landed cost of active pharmaceutical ingredients (APIs), excipients and packaging materials sourced from Asia.
For procurement teams operating in highly competitive OTC markets, these transportation costs are becoming a significant factor in product profitability.
Freight Inflation Is Reshaping Procurement Economics
Historically, transportation represented a relatively small portion of the total cost structure for many pharmaceutical ingredients.
In 2026, that assumption is changing.
Freight rates on major Asia-Europe and Asia-North America routes have surged well above historical norms, creating additional cost pressure for manufacturers that rely on imported raw materials.
The impact is particularly visible in:
Generic OTC medicines
Consumer healthcare products
Nutritional supplements
Personal care formulations
Commodity pharmaceutical ingredients
Products with already thin margins are experiencing the greatest pressure.
Why CHC and OTC Manufacturers Are Especially Vulnerable
Unlike innovative pharmaceutical products, many OTC and consumer healthcare products compete in highly price-sensitive markets.
Manufacturers often face:
Retail pricing pressure
Private-label competition
Limited pricing flexibility
High-volume production requirements
As freight expenses increase, companies cannot always pass those costs directly to customers.
Instead, procurement teams must find ways to protect margins through supply chain optimization and sourcing strategies.
China and India Remain Critical Supply Sources
A substantial portion of global pharmaceutical raw material supply continues to originate from:
China
India
These countries remain leading exporters of:
APIs
Pharmaceutical intermediates
Excipients
Nutritional ingredients
Packaging materials
While manufacturing costs may remain competitive, higher transportation expenses are increasing total delivered costs.
As a result, procurement decisions are increasingly based on landed cost rather than simply factory pricing.
Consumer healthcare (CHC) and over-the-counter (OTC) pharmaceutical manufacturers are facing a new challenge in 2026 that has little to do with formulation science or regulatory approvals.
The issue is logistics.
After months of disruption across global shipping networks, freight rates on key pharmaceutical trade lanes have climbed sharply, increasing the landed cost of active pharmaceutical ingredients (APIs), excipients and packaging materials sourced from Asia.
For procurement teams operating in highly competitive OTC markets, these transportation costs are becoming a significant factor in product profitability.
Freight Inflation Is Reshaping Procurement Economics
Historically, transportation represented a relatively small portion of the total cost structure for many pharmaceutical ingredients.
In 2026, that assumption is changing.
Freight rates on major Asia-Europe and Asia-North America routes have surged well above historical norms, creating additional cost pressure for manufacturers that rely on imported raw materials.
The impact is particularly visible in:
Generic OTC medicines
Consumer healthcare products
Nutritional supplements
Personal care formulations
Commodity pharmaceutical ingredients
Products with already thin margins are experiencing the greatest pressure.
Why CHC and OTC Manufacturers Are Especially Vulnerable
Unlike innovative pharmaceutical products, many OTC and consumer healthcare products compete in highly price-sensitive markets.
Manufacturers often face:
Retail pricing pressure
Private-label competition
Limited pricing flexibility
High-volume production requirements
As freight expenses increase, companies cannot always pass those costs directly to customers.
Instead, procurement teams must find ways to protect margins through supply chain optimization and sourcing strategies.
China and India Remain Critical Supply Sources
A substantial portion of global pharmaceutical raw material supply continues to originate from:
China
India
These countries remain leading exporters of:
APIs
Pharmaceutical intermediates
Excipients
Nutritional ingredients
Packaging materials
While manufacturing costs may remain competitive, higher transportation expenses are increasing total delivered costs.
As a result, procurement decisions are increasingly based on landed cost rather than simply factory pricing.
2-Ethylhexyl Acrylate CAS: 103-11-7
